Sorafenib-induced hand-foot skin reaction

Sorafenib is a multikinase inhibitor approved for renal cell carcinoma and hepatocellular carcinoma. Although an effective antitumor agent, it is associated with significant adverse effects as well. Hand-foot skin reaction (HFSR) is a cutaneous adverse effect which involves erythematous, bullous, hyperkeratotic, and ulcerative lesions over hands and feet. We report a case of Grade 2 HFSR with bullous- and callus-like hyperkeratotic lesions due to sorafenib which responded well to symptomatic treatment only without any dose reduction or discontinuation of chemotherapy.